https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=168877&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MO ...